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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: : Two critical challenges in developing cell-transplantation therapies for injured or
diseased tissues are to identify optimal cells and harmful side effects. This is of particular
concern in the case of spinal cord injury, where recent studies have shown that transplanted
neuroepithelial stem cells can generate pain syndromes.
R Re es su ul lt ts s: : We have previously shown that astrocytes derived from glial-restricted precursor
cells (GRPs) treated with bone morphogenetic protein-4 (BMP-4) can promote robust axon
regeneration and functional recovery when transplanted into rat spinal cord injuries. In
contrast, we now show that transplantation of GRP-derived astrocytes (GDAs) generated by
exposure to the gp130 agonist ciliary neurotrophic factor (GDAsCNTF), the other major
signaling pathway involved in astrogenesis, results in failure of axon regeneration and
functional recovery. Moreover, transplantation of GDACNTF cells promoted the onset of
mechanical allodynia and thermal hyperalgesia at 2 weeks after injury, an effect that persisted
through 5 weeks post-injury. Delayed onset of similar neuropathic pain was also caused by
transplantation of undifferentiated GRPs. In contrast, rats transplanted with GDAsBMP did not
exhibit pain syndromes.
C Co on nc cl lu us si io on ns s: : Our results show that not all astrocytes derived from embryonic precursors are
equally beneficial for spinal cord repair and they provide the first identification of a
differentiated neural cell type that can cause pain syndromes on transplantation into the
damaged spinal cord, emphasizing the importance of evaluating the capacity of candidate cells
to cause allodynia before initiating clinical trials. They also confirm the particular promise of
GDAs treated with bone morphogenetic protein for spinal cord injury repair.
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Two critical challenges that must be addressed in the
development of cell-based tissue repair strategies are the
identification of optimal cell types and the identification of
instances in which cell transplantation may create severe
adverse side effects. The first problem is important because
of the considerable resources that will be required to
establish clinical efficacy of putative treatments. The second
problem is perhaps of even greater importance, because
adverse outcomes in clinical trials could seriously hinder
the development of stem cell technology for tissue repair.
Diseases of the central nervous system (CNS) are of
particular interest as candidates for clinical evaluation of
cell transplantation therapies, with the treatment of spinal
cord injury being one of the primary targets for early
translation of laboratory efforts to clinical trials. A variety
of cell types of both non-CNS and CNS origin, such as
Schwann cells [1], olfactory ensheathing glia [2], marrow
stromal cells [3,4] and oligodendrocyte progenitor cells
[5], are being considered for clinical trial to treat spinal
cord injuries. One of the most attractive reasons for
considering the use of non-CNS cells such as Schwann
cells, olfactory ensheathing cells and marrow stromal cells
for CNS repair has been their relative ease of isolation
compared to cells of CNS origin. However, continuing
advances in stem cell technology are making the goal of
utilizing CNS cell types to repair the injured CNS more
readily attainable.
One new potential candidate for use in CNS repair is a
population of astrocytes that is derived by treatment of
glial progenitor cells (GRPs) of the embryonic spinal cord
with bone morphogenetic protein (BMP) before trans-
plantation. We call this astrocyte population GDAsBMP.
The replacement of damaged neurons and oligo-
dendrocytes in the injured or diseased spinal cord has
been pursued by a number of laboratories (reviewed in
[6]), but less attention has been given to the development
of astrocyte replacement therapies, despite the fact that
astrocytes account for the majority of cells in the adult
CNS [7] and are critical to normal CNS function [8]. This
relative lack of attention is probably due to the modest
levels of axon regeneration and lack of functional recovery
seen after transplantation into the injured CNS of astro-
cytes isolated from the immature cortex [9-12]. Factors
such as contamination with microglia and undifferen-
tiated progenitors, isolation from cortex rather than spinal
cord, and a phenotype that is less supportive of axon
growth (resulting from the prolonged in vitro growth
required to generate postnatal astrocyte cultures) [13],
may have rendered these glial cultures suboptimal for
repairing the injured adult spinal cord.
In contrast to the lack of effect of astrocyte transplantation
in previous studies, GDAsBMP promote robust axon
regeneration, neuroprotection and functional recovery after
acute spinal cord injury [14]. The ability to generate specific
subtypes of astrocytes from defined glial precursors provides
a new platform for the development of astrocyte-based
transplantation therapies for the injured adult CNS.
Transplantation of GDAsBMP to acute transection injuries of
adult rat spinal cord promoted first, a 39% efficiency of
endogenous ascending dorsal column axon regeneration
across sites of injury; second, protection of axotomized red
nucleus neurons; third, a significant reduction of inhibitory
scar formation; and fourth, a degree of behavioral recovery
from dorsolateral funiculus injuries that enabled rats to
generate an average score by 4 weeks after transplantation
that was statistically indistinguishable from that obtained
for uninjured animals on a stringent test of volitional foot
placement [14]. Moreover, this strategy allows the rapid
generation of astrocytes directly from embryonic precursor
cells, thus eliminating the use of the prolonged in vitro
purification procedures that result in a phenotype that is
less supportive of axon growth [13].
Recent studies demonstrating the ability of transplanted
neuroepithelial stem cells (NSCs) to cause pain syndromes
in animals with spinal cord injury have, however, raised
concerns that the astrocytes generated by transplanted stem
or progenitor cells might cause adverse effects that outweigh
any benefits. Two recent studies have shown that trans-
plantation of NSCs into acute spinal cord injuries in rats
promotes the onset of both mechanical allodynia (a painful
response to normally non-painful touch stimuli) and
thermal hyperalgesia (abnormal sensitivity to heat) [15,16].
These adverse side effects correlated with the differentiation
of the transplanted NSCs into astrocytes, and were
prevented by the suppression of astrocyte generation by
overexpression of the transcription factor neurogenin-2 in
the transplanted NSCs [15]. It was therefore very important
to determine whether transplantation of astrocytes, or of
precursor cells capable of generating astrocytes, would
promote the onset of allodynia, or whether this is a
problem unique to the transplantation of NSCs.
The study reported here was carried out to determine
whether all astrocytes generated from GRPs [17] were
equally able to promote repair of adult injured spinal cord.
Two types of astrocytes can be generated from embryonic
spinal GRPs - GDAsBMP and GDAsCNTF (astrocytes derived
from the gp130 receptor agonist ciliary neurotrophic factor
(CNTF)). We found that transplantation of these two types
of astrocytes into acute spinal cord injuries (Figure 1)
yielded significantly different outcomes. In contrast to
GDAsBMP, we found that GDAsCNTF provided no benefit
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or undifferentiated GRPs caused neuropathic pain. Our
results also confirm earlier work [14] showing that trans-
plantation of GDAsBMP generated by controlled pre-differen-
tiation of GRPs can provide substantial benefits after spinal
cord injury and that this pre-differentiation can avoid the
problem of transplanted glial precursors themselves causing
pain syndromes.
R Re es su ul lt ts s
C Ch ha ar ra ac ct te er ri iz za at ti io on n   o of f   G GD DA As s   i in n   v vi it tr ro o
GRPs exposed to BMP-4 generate astrocytes (GDAsBMP) with
a flat, type-1 antigenic phenotype that express glial fibrillary
acidic protein (GFAP) and do not label with the A2B5 anti-
body [14]. In contrast, GRPs grown in the presence of the
gp130 receptor agonist CNTF generate GFAP+ astrocytes
(GDAsCNTF) with processes that are labeled by A2B5 [17]. In
seeking to use GDAs for repairing the injured spinal cord, it
is critical to know whether the favorable properties of
GDAsBMP are solely a reflection of the embryonic age and/or
identity of the glial precursor cell from which they are
derived, or whether it is necessary to generate a very specific
population of astrocytes from these precursor cells to
promote repair.
To answer this question, we first characterized GDAsBMP and
GDAsCNTF in vitro and found that GDAsCNTF had properties
suggesting they would be less suitable than GDAsBMP for
repairing the injured adult CNS. Compared with GDAsBMP,
GDAsCNTF express elevated levels of the axon-growth-
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Schematic illustration of the adult rat models of spinal cord injury used in this study. ( (a a) )   Dorsal view of rat brain and spinal cord. Dorsal column
white matter on the right side was transected (shaded area) at the C1/C2 spinal level, and the ability of either BDA-labeled endogenous axons or
axons from microtransplanted GFP-expressing adult sensory neurons (DRGs) to cross injuries bridged with GDAs or GRPs was assayed. 
( (b b) ) Horizontal and ( (c c) ) sagittal views of the dorsal column white-matter pathways at the C1/C2 cervical vertebrae of the spinal cord. (b) Injections of
GDAs or GRPs (black diamonds) suspended in medium were made directly into the centers of the injury sites as well as their rostral and caudal
margins in the cervical spinal cord. ( (c c) ) A discrete population of endogenous ascending axons within the cuneate and gracile white-matter pathways of
dorsal columns was labeled by BDA injection at the C4/C5 spinal level (5 mm caudal to the injury site, shaded). Alternatively, microtransplants of
GFP+ DRGs were injected 500 µm caudal to the injury site. ( (d d) ) The right-side dorsolateral funiculus white matter containing descending axons of the
rubrospinal tract was transected at the C3/C4 spinal level and GDAs or GRPs were transplanted as described for dorsal column injuries. CC, central
canal; Cf, cuneate fasciculus; CST, corticospinal tract; DF, dorsolateral funiculus; Gf, gracile fasciculus; GM, gray matter; RN, red nucleus; RST,
rubrospinal tract; T1, level of the first thoracic vertebra.
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(Figure 2a,b) and phosphacan (Figure 2c,d), both of which
are also expressed at high levels in glial scar tissue [18]. We
also found that GDAsBMP and GDAsCNTF cells differed in
their regulation of the transcriptional regulator Olig2 in vitro
(Figure 3a,b). In agreement with previous observations of
the effects of BMP on Olig2 expression in cortical neural
progenitors [19], GRPs exposed to BMP-4 downregulated
Olig2 expression (Figure 3a). In contrast, GDAsCNTF had
high levels of Olig2 in their nuclei (Figure 3b). Several
recent studies have reported the natural generation of cells
that coexpress Olig2 and GFAP in vivo after injury to the
brain [20,21]. Although those studies described cytoplasmic
rather than nuclear localization of Olig2, our examination
of control injured spinal cords at 8 days revealed the
presence of endogenous GFAP+ cells with nuclear
localization of Olig2 (Figure 3c).
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GDAsBMP, GDAsCNTF and GRPs express different levels of NG2 and
phosphacan in vitro. GRPs were induced to differentiate into 
astrocytes by exposure to BMP or CNTF. Relative levels of expression
of NG2 and phosphacan proteins were determined by quantitative
Western blot and immunocytochemical analysis. ( (a a, ,c c) ) Western blot
analysis of whole-cell lysates demonstrates that GDAsCNTF express
higher levels of (a) NG2 and (c) phosphacan. The graph shows fold
change in protein levels for GDAs compared to GRPs. Error bars
represent 1 standard deviation (SD). *p < 0.05. ( (b b, ,d d) )   Immuno-
fluorescent labeling of cells using (b) anti-NG2 antibodies and (d) anti-
phosphacan. Scale bars 50 µm.
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Differential expression of Olig2 protein by different astrocyte
populations. ( (a a) ) GDAsBMP do not express Olig2. ( (b b) )   In sharp contrast,
GDAsCNTF are uniformly immunopositive for Olig2 in vitro. ( (c c) ) A
subset of endogenous GFAP+ astrocytes in the margins of untreated
dorsal column spinal cord injuries is also Olig2-immunoreactive.
Survival, 8 days post-injury. Note the nuclear localization of Olig2 in
GDAsCNTF in vitro and in reactive, endogenous GFAP+ astrocytes in
vivo. Scale bars: (a,b) 50 µm; (c) 25 µm.
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Transplanted GDAsCNTF exhibited good survival and were
able to completely span sites of injury (Figures 4-7). We
found that transplanted GDAsCNTF displayed phenotypes
markedly different from those previously observed for
transplanted GDAsBMP. The majority of GDAsCNTF retained
their GFAP immunoreactivity after transplantation to acute
spinal cord injury, particularly for those cells adjacent to
injury margins (Figure 4a). Subsets of intra-injury GDAsCNTF
also displayed immunoreactivity for the axon-growth-
inhibitory proteoglycan neurocan at 4 and 8 days post-
injury (Figure 4b) and the majority of GDAsCNTF had
retained their in vitro immunoreactivity for NG2 (Figure 5).
In contrast, our previous studies showed that GDAsBMP did
not retain GFAP immunoreactivity after transplantation to
identical acute spinal cord injuries [14]. More importantly,
transplanted GDAsBMP within the center of the injured site
remained negative for neurocan and NG2 immunoreactivity
at 8 days after transplantation [14].
E Ef ff fe ec ct ts s   o of f   G GD DA As sC CN NT TF F a an nd d   G GR RP Ps s   o on n   s sc ca ar r   f fo or rm ma at ti io on n
Transplanted GDAsCNTF and GDAsBMP also had substantially
different effects on the reactivity of host astrocytes at sites of
injury. We previously showed that transplantation of
GDAsBMP suppressed the gliotic response of host astrocytes
within injury margins and promoted a remarkable lineariza-
tion of their processes [14]. Transplantation of GDAsCNTF, in
contrast, did not suppress astrogliosis, nor did these cells
align host astrocytes in injury margins. Instead, the margins
of GDACNTF-transplanted injury sites contain a meshwork of
misaligned, hypertrophic GFAP+ astrocytic processes
(Figure 4a), similar to that observed in both control un-
treated injuries and the margins of GRP-transplanted injuries
[14]. GDACNTF and GRP transplantation did, however, result
in a suppression of neurocan and NG2 expression by host
tissue at sites of injury at 4 days post-injury, an effect we
previously observed following transplantation of GDAsBMP
[14]. At 4 days after injury, the margins of control, untreated
injuries displayed a high density of neurocan immuno-
reactivity (Figure 6a) associated with numerous fine GFAP-
processes that we previously showed to be associated with
NG2+ glia [18]. In contrast, at 4 days after injury and
transplantation of GDAsCNTF (Figure 6b,c) or GRPs
(Additional data file 1), neurocan immunoreactivity within
injury margins was mainly associated with the cell bodies of
GFAP+ host white-matter astrocytes, a pattern of expression
similar to that observed for neurocan at 2 days after injury
in untreated control animals [18]. However, by 8 days after
injury and GDACNTF transplantation, neurocan and NG2
immunoreactivity at sites of injury was similar in intensity
and distribution to that seen in untreated control injuries
(Figures 4b and 5b). Thus, like GDAsBMP transplanted to
acute spinal cord injuries, GRPs and GDAsCNTF had
promoted transient suppression of axon-growth-inhibitory
CSPGs by host tissues; but unlike GDAsBMP, neither
GDAsCNTF nor GRPs [14] suppressed astrogliosis or aligned
host astrocytes within injury margins.
G GD DA As sC CN NT TF F d do o   n no ot t   s su up pp po or rt t   a ax xo on n   r re eg ge en ne er ra at ti io on n   i in n   v vi iv vo o
We next examined the ability of GDAsCNTF to promote axon
regeneration in vivo, both of endogenous ascending dorsal
column axons and of axons emanating from transplanted
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GDAsCNTF express GFAP and neurocan after transplantation into spinal
cord injuries. ( (a a) ) Intra-injury GDAsCNTF are uniformly GFAP+ within
acute dorsal column injuries. Note the co-localization (yellow) of
human placental alkaline phosphatase (hPAP, red) with GFAP (green).
GDAsCNTF have also failed to align host astrocytic processes within
injury margins. Survival, 8 days post-injury/transplantation. ( (b b) ) High-
magnification confocal image of neurocan immunoreactivity at the injury
margin and within a GDACNTF-transplanted injury site at 8 days after
injury/transplantation. Note that some GDAsCNTF are immunoreactive
for neurocan (green). In contrast, intra-injury transplanted GDAsBMP
(not shown) do not express GFAP or neurocan, and can align host
astrocytic processes within injury margins [14]. Scale bars 100 µm.
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Neurocanadult dorsal root ganglion (DRG) neurons. For analysis of
endogenous axon regeneration, a discrete population of
ascending axons aligned with the injury site was traced with
a single injection of biotinylated dextran amine (BDA) at a
distance 6 mm caudal to GDACNTF-, GDABMP-, or GRP-trans-
planted or control transection injuries of the right-hand
dorsal column cuneate and gracile white-matter pathways.
This minimized the labeling of spared axons. Previous
studies have shown that around 30-40% of ascending
dorsal column axons projecting to the dorsal column nuclei
arise from postsynaptic dorsal column neurons in spinal
lamina IV and that 25% of ascending dorsal column axons
are also propriospinal in origin [22,23]. It has been shown
that only 15% of primary afferents of DRG neurons entering
the spinal cord at lumbar levels reach the cervical spinal
cord and that most leave dorsal column white matter within
two to three segments of entering [24]. Therefore, our en
passage labeling of dorsal column axons at the cervical level
would have included significant proportions of axons from
both CNS spinal neurons and DRG neurons. To further test
the ability of transplanted GDAsCNTF to support axon growth
across an acute spinal cord injury in a model that eliminates
the possibility of axon sparing, we examined their ability to
support the growth of adult sensory axons across identical
stab injuries in an adult DRG neuron/GDA transplant
spinal cord injury model [14]. In these experiments, a
separate series of animals received microtransplants of adult
mouse sensory neurons labeled with green fluorescent
protein (GFP) acutely into dorsal column white matter at a
distance of 400-500 µm caudal to GDACNTF-transplanted
injuries (Figure 1c).
Transplantation of either GRPs or GDAsCNTF to acute dorsal
column transection injuries failed to improve the regenera-
tion of endogenous ascending dorsal column axons above
that observed in untreated injuries (Figure 7). There was
also a complete failure of axons grown from adjacent micro-
transplanted adult mouse DRG neurons expressing enhanced
green fluorescent protein (EGFP) to cross GDACNTF-trans-
planted injuries (Additional data file 2). In both experi-
mental models, the majority of axons instead formed
dystrophic endings within the caudal injury margins of
GDACNTF-transplanted injuries, (Figure 7a and Additional
data file 2a), an axon morphology well known as the
hallmark of failure of axon regeneration in CNS injury
[25,26]. Quantitative analysis of the efficiency of ascending
dorsal column axon regeneration in GDACNTF- and GRP-trans-
planted rats at 8 days after transplantation/injury showed
that only 7% (SD ± 2.0) and 5.3% (SD ± 3.0), respectively,
of BDA-labeled axons within white matter 0.5 mm caudal
to injury sites had reached injury centers; 6.2% (SD ± 3.5)
and 4.7% (SD ± 3.9) of axons had extended 0.5 mm
beyond injury sites into distal white matter, with 4.6%
(SD ± 2.3) and 4.2% (SD ± 3.6) reaching 1.5 mm beyond
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NG2 immunoreactivity in GDACNTF-transplanted dorsal column injuries. ( (a a) )   Transplanted hPAP+ GDAsCNTF (arrowheads) at 8 days post
injury/transplantation. ( (b b) )   The same slide stained for NG2 (green) showing that the transplanted cells (arrowheads) show immunoreactivity for NG2.
( (c c) ) Co-localization (yellow) of NG2 and hPAP immunoreactivity in regions containing higher densities of GDAsCNTF (arrowheads). In general, regions
of the injury site that contained higher densities of hPAP+ GDAsCNTF had a higher density of NG2 immunoreactivity. Scale bars 50 µm.
(a) (b) (c) GDACNTF NG2 GDACNTF
NG2injury sites (Figure 7c). No BDA-labeled axons were
detected beyond 1.5 mm in distal white matter or within
the dorsal column nuclei of both GDACNTF- and GRP-
transplanted rats (Figure 7c). All the percentages of BDA-
labeled axons within injury sites and at all points beyond
were not statistically different from those quantified for
BDA-labeled endogenous ascending dorsal column axons in
identical control, untransplanted injuries [14] (ANOVA,
p > 0.05).
The failure of both GDAsCNTF and GRPs (see also [14]) to
support axon regeneration is in stark contrast to the ability
of transplanted GDAsBMP to promote regeneration of
endogenous dorsal column axons across spinal cord
injuries. In GDABMP-transplanted animals, 55% (SD ± 8.0) of
labeled axons extended to the injury center, 36.5% (SD ± 11.0)
extended to 0.5 mm beyond the injury site, and 30.4%
(SD ± 9.2) had extended to 1.5 mm beyond the injury site
(Figure 7c). Furthermore, 12.6% (SD ± 9.0) of labeled axons
were detected within white matter at 5 mm beyond the
injury site, and 2.1% (SD ± 1.4) were observed within the
dorsal column nuclei (Figure 7c). This is consistent with our
previous finding that intra-injury transplants of GDABMP
cells promote regeneration of 60% (SD ± 11.0) of labeled
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Transplanted GDAsCNTF express neurocan and NG2, but suppress host expression of these two CSPGs at 4 days post-injury/transplantation. ( (a a) ) At
4 days after injury, control dorsal column injury margins express dense neurocan immunoreactivity (green) mainly associated with GFAP- processes.
Note the absence of neurocan immunoreactivity in the injury center (to the left). ( (b b, ,c c) ) While neurocan immunoreactivity in host white matter was
markedly lower and mainly associated with astrocyte cell bodies, many intra-injury GDAsCNTF within injury centers displayed neurocan
immunoreativity. ( (d d) ) NG2 immunoreactivity in control injuries is high in both injury centers and margins. ( (e e, ,f f) ) Although overall levels of NG2
immunoreactivity were reduced within injury centers and margins of GDACNTF-transplanted injury sites compared to untreated control injuries
(compare (d) and (f)), levels of NG2 immunoreactivity were still higher than that previously observed for identical dorsal column injuries
transplanted with GDAsBMP [14]. Scale bars 200 µm.
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Failure of axons to regenerate across GDACNTF or GRP transplanted dorsal column injuries. ( (a a) ) Biotinylated dextran amine (BDA)-labeled endogenous,
ascending dorsal column axons (green) fail to cross GDACNTF-transplanted injury sites and instead form dystrophic endings within caudal injury
margins. While a few axons sprout towards the injury center, BDA+ axons are rarely detected beyond the injury/transplantation site at 8 days post-
injury/transplantation. Scale bar 200 µm. ( (b b) ) In contrast, transplanted GDAsBMP support extensive axon growth across dorsal column injuries at 8 days
after injury/transplantation. Scale bar 200 µm. ( (c c) ) Quantification of numbers of regenerating BDA+ axons in GDA- or GRP-transplanted dorsal column
white matter at 8 days after injury and transplantation. BDA-labeled axons were counted in every third sagittally oriented section within the injury
center and at points 0.5 mm, 1.5 mm and 5 mm rostral to the injury site and within the dorsal column nuclei (DCN). Note that 55% of BDA+ axons
reached the centers of GDABMP-transplanted injuries, and 36% to 0.5 mm beyond the injury site. After GDACNTF or GRP transplantation, however,
only 7% and 5.3% of BDA+ axons, respectively, were observed within injury centers, with only 4.6% and 4.2% of the axons observed at 0.5 mm beyond
the injury site. No BDA+ axons were detected beyond 1.5 mm rostral to the injury site in GDACNTF- or GRP-transplanted spinal cords. Error bars
represent 1 SD.
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BDAendogenous ascending dorsal column axons into the center of
injury sites, and more than two-thirds of these axons were
within white matter beyond the injury site by 8 days after
transplantation/injury [14].
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To make a direct comparison of the ability of GDAsCNTF and
GDAsBMP to promote functional recovery following dorso-lateral
funiculus transection injuries to the spinal cord, an analysis of
grid-walk performance for GDACNTF- and GDABMP-transplanted
rats versus rats injected with control medium was carried out at
times ranging from 3 to 28 days after injury/transplantation.
Transection of the dorsolateral funiculus severs descending
supraspinal axons and results in chronic deficits in both fore-
and hindlimb motor function [27] that can be detected by the
grid-walk behavioral test [28]. We have previously shown that
transplantation of GDAsBMP into acute dorsolateral funiculus
injuries resulted in robust improvements in grid-walk locomotor
function compared to media-injected control injured animals at
all time points ranging from 3 to 28 days post-injury. In contrast,
transplantation of undifferentiated GRPs failed to improve scores
to greater than those observed for control injured animals [14].
Animals that received GDACNTF transplants or injections of
medium alone (controls) made an average of 6.2 (SD ± 0.5)
and 6.0 (SD ± 0.3) mistakes, respectively, at 3 days after
injury/transplantation and showed no statistically significant
improvement at any later time point, with an average of 5.2
(SD ± 0.3) and 5.0 (SD ± 0.9) mistakes at 28 days post-injury
(Figure 8). Thus, despite receiving transplants of astrocytes
derived from embryonic GRP cells, GDACNTF-transplanted rats
did not show any recovery of locomotor function when
compared with controls. In contrast, at 3 days after
injury/transplantation, animals receiving GDAsBMP were
already making an average of 4.5 (SD ± 0.3) mistakes; that is,
significantly fewer than GDACNTF-transplanted or control
animals (Figure 8). Consistent with our previous report [14],
animals receiving GDABMP transplants in the current study
continued to improve significantly between 3 and 28 days after
injury (two-way repeated measures ANOVA, p < 0.05). At 28
days after injury, GDABMP-treated rats made an average of just
1.7 (SD ± 0.3) mistakes on the grid walk apparatus (Figure 8), a
score that was statistically indistinguishable from their pre-
injury baseline scores.
T Tr ra an ns sp pl la an nt ta at ti io on n   o of f   G GD DA As sC CN NT TF F o or r   G GR RP Ps s   f fa ai il ls s   t to o   s su up pp pr re es ss s
a at tr ro op ph hy y   o of f   r re ed d   n nu uc cl le eu us s   n ne eu ur ro on ns s
Transection of axons of the rubrospinal tract (RST) in the
dorsolateral funiculus of the spinal cord causes atrophy of
significant numbers of red nucleus neurons, a process that
begins approximately 1 week after spinal cord injury [29].
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Grid-walk analysis of locomotor recovery. Graph showing the average
number of missed steps per experimental group from 1 day before
injury (baseline pre-injury) to 28 days after injury for all GDA-
transplanted/dorsolateral funiculus injured rats versus the control-
injured animals. GDABMP-transplanted animals (green) performed
significantly better than GDACNTF-transplanted animals and injured
control animals at all post-injury time points (p < 0.05). Note that the
performance of GDACNTF-transplanted animals was not different from
untreated control injured rats at all time points (two-way repeated
measures ANOVA, *p < 0.05). N = 9 rats per group.
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Neuroprotection of red nucleus neurons. Injured left-side red nuclei
contained an average of 52% of the neurons counted in uninjured right-
side red nuclei at 5 weeks after transection of the right-side rubrospinal
tract. The numbers of neurons in the injured left-side red nuclei of
GRP- and GDACNTF-transplanted animals were no different from
controls, and contained an average of 55% and 51%, respectively, of the
neurons counted in the uninjured right-side nuclei. In contrast, the
number of neurons in the injured left-side red nuclei of GDABMP-
transplanted animals was 81% of the total number of neurons in
uninjured right-side nuclei. *p < 0.01. Error bars represent 1 SD.
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a cell-body diameter greater than 20 µm in the injured left-
side red nucleus in control, untreated RST-injured animals
fell to 52% (SD ± 4.2%) of the values in the uninjured right-
side nucleus at 5 weeks after injury (Figure 9).
Consistent with our previous findings [14], animals that
had received intra-spinal cord injury transplants of GDAsBMP
(Figure 9) once again showed a significant suppression of red
nucleus neuron atrophy with 82% (SD ± 6.1) of neurons in
the injured left-side red nucleus having cell body diameters
greater than 20 µm when normalized to the uninjured right-
side nucleus (Figure 9). In contrast, transplantation of
GDAsCNTF or undifferentiated GRPs into identical dorso-
lateral funiculus injuries completely failed to suppress
neuron atrophy in the injured left-side red nucleus (Figure 9;
see also Additional data file 3). Counts of neurons with a
cell-body diameter greater than 20 µm in the injured left-
side red nucleus in GDACNTF- or GRP-treated animals were
only 51% (SD ± 8.7%) and 55% (SD ± 8.0%), respectively,
of the values in uninjured right-side red nucleus at 5 weeks
after injury and did not differ statistically from untreated
injured animals (ANOVA, p < 0.05). Thus, despite the fact
that GDAsBMP and GDAsCNTF are both astrocytes derived
from the same embryonic precursor cells, they do not share
the same ability to rescue red-nucleus neuronal populations
from atrophy.
G GD DA As sC CN NT TF F o or r   G GR RP Ps s, ,   b bu ut t   n no ot t   G GD DA As sB BM MP P, ,   i in nd du uc ce e   m me ec ch ha an ni ic ca al l
a al ll lo od dy yn ni ia a   a an nd d   t th he er rm ma al l   h hy yp pe er ra al lg ge es si ia a   w wh he en n   t tr ra an ns sp pl la an nt te ed d   i in nt to o
s si it te es s   o of f   s sp pi in na al l   c co or rd d   i in nj ju ur ry y
To test whether transplantation of GDAsBMP, GDAsCNTF and
GRPs might promote the induction of mechanical allodynia
and thermal hyperalgesia in acute spinal cord injuries,
initial experiments were carried out to test for increases in
mechanical and thermal sensitivity in control rats receiving
injections of medium into transection injuries of the right-
side dorsolateral funiculus at 2, 3, 4, and 5 weeks after injury.
Importantly, compared with pre-injury scores, injured
medium-injected control rats did not show statistically
significant increases in gram force withdrawal thresholds for
right-side forepaws in response to application of graded
Von Frey filaments at all time points after injury and trans-
plantation (Figure 10a). Similarly, analysis of paw-
withdrawal response latencies to an experimental heat
source pre- and post-injury revealed no statistically signifi-
cant induction of thermal hyperalgesia in injured controls at
all time points post-injury (Figure 10b). These results
enable a direct comparison of the effects of intra-injury trans-
plantation of GDAsBMP, GDAsCNTF or GRPs on the induction
of mechanical allodynia and thermal hyperalgesia in rats with
identical dorsolateral funiculus transection injuries.
Unlike animals that received GDAsCNTF or GRPs, GDABMP-
transplanted animals did not show a statistically significant
increase in sensitivity to mechanical or heat stimuli at any
times (2, 3 and 4 weeks) up to 5 weeks post-injury
(Figure 10a,b) compared to pre-injury responses (two-way
repeated measures ANOVA, p > 0.05). GDACNTF-transplanted
animals showed a significant increase in sensitivity to both
mechanical and heat stimuli by 2 weeks after injury, an
effect that persisted to 5 weeks after injury, the last time
point tested (Figure 10a,b). Animals that received intra-
24.10 Journal of Biology 2008, Volume 7, Article 24 Davies et al. http://jbiol.com/content/7/7/24
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Von Frey filament and hot-plate analysis of mechanical and thermal
allodynia. ( (a a) ) Withdrawal threshold of the right front paw to a
mechanical stimulus (force in grams). Measurements were made on
GRP- or GDA-transplanted and injured control animals at 2, 3, 4 and 5
weeks after dorsolateral funiculus injury/transplantation. ( (b b) ) Latency (in
seconds) to paw withdrawal from a heat source. Note that injury alone
and GDABMP transplantation do not induce statistically significant
mechanical or thermal allodynia at any time point. However, the
mechanical threshold and latency to withdrawal from a heat source are
significantly lower in GDACNTF- and GRP-transplanted rats beginning at
2 and 3 weeks, respectively, post-injury/transplantation. Asterisks
denote a statistical difference from time-matched control animals (two-
way repeated measures, ANOVA, p < 0.05). Error bars represent 1 SD.
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*injury transplants of undifferentiated GRPs also developed
increased sensitivity to both mechanical and heat stimuli,
although with a delayed time course. GRP-transplanted
animals began to show mechanical allodynia and thermal
hyperalgesia at 3 weeks post injury and transplantation,
effects that persisted to 5 weeks post-injury (Figure 10a,b).
G GD DA As sC CN NT TF F a an nd d   G GR RP Ps s   p pr ro om mo ot te e   s sp pr ro ou ut ti in ng g   o of f   C CG GR RP P   c c- -f fi ib be er rs s
a af ft te er r   s sp pi in na al l   c co or rd d   i in nj ju ur ry y
Previous studies have shown a correlation between sprouting of
calcitonin-gene-related peptide (CGRP) immunoreactive
nociceptive c-fibers within lamina III of the dorsal horn and the
development of neuropathic pain after spinal cord injury [30].
To assay for this, we carried out a comparative quantitative
analysis at 5 weeks post-injury of the density of CGRP
immunoreactivity in lamina III of the dorsal horn at spinal level
C6 ipsilateral to injury sites in media-injected injured controls,
and GDABMP-, GDACNTF- or GRP-transplanted animals. Notably,
the GDABMP-transplanted animals showed no statistically
significant change in the density of CGRP-positive c-fibers
compared with the control injured animals (Figure 11). This
result correlated with the absence of statistically significant
mechanical allodynia and thermal hyperalgesia in GDABMP-
treated animals compared with uninjured controls.
In contrast, significant increases in the density of CGRP
immunoreactivity were found in animals that received intra-
injury transplants of GDAsCNTF or GRPs. Comparison of the
density of CGRP immunoreactivity in GDACNTF-, GRP- and
GDABMP-transplanted cords revealed 2.6- and 2.9-fold increases
for GDACNTF- and GRP-treated cords, respectively, above levels in
GDABMP-transplanted cords at 5 weeks post-injury (Figure 11).
These results demonstrate that transplantation of GDAsCNTF
or GRPs, but not of GDAsBMP, into spinal cord injuries
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Aberrant CGRP+ c-fiber sprouting into lamina III of GDACNTF- or GRP-
transplanted spinal cords that have received dorsolateral funiculus
transection injuries. The density of pixels within images of lamina III of
the right-side dorsal horn caudal to the injury and transplantation site in
GDA- or GRP-transplanted, or injury-only control animals is presented
as the average percentage of CGRP+ pixels per total pixels (area) of
lamina III. ( (a a) )   Averages of 5.7% and 6.2% of the total pixels in lamina III
were CGRP+ in GDACNTF- and GRP-transplanted spinal cords,
respectively. In contrast, only 2.2% and 3.4% of lamina III pixels were
CGRP+ in GDABMP-transplanted and injury-only spinal cords. The
asterisk indicates significant difference from both control injury-only
and GDABMP-transplanted groups (two-way repeated measures
ANOVA, p < 0.05). Error bars represent 1 SD. ( (b b- -e e) ) Sample images of
sections labeled with anti-CGRP antibodies from rats transplanted at
the spinal C6 level: (b) control, (c) GDABMP, (d) GDACNTF and (e) GRP.
Area enclosed with a dashed line in (b-e) indicates lamina III. Note the
increased density of CGRP+ immunoreactivity within lamina III of the
dorsal horn of (d) GDACNTF- and (e) GRP-treated spinal cords
compared to (b) control injured and (e) GDABMP- treated spinal cords.
Scale bar 200 µm.
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Effect GDAsBMP GDAsCNTF GRPs
Promote axon growth  +++ - -
across spinal cord injury
Promote locomotor recovery +++ - -
Suppress atrophy of injured  +++ - -
red nucleus neurons
Induce mechanical and  - +++ +++
thermal allodynia
Promote sprouting of CGRP+ - +++ +++
axons in lamina III
Align host astrocytes at injury site +++ - -
Transiently suppress host  +++ +++ +++
CSPG expression
Express inhibitory CSPGs  - +++ +++
within injury site
Express CSPGs in vitro + +++ +++induces both mechanical allodynia and thermal hyper-
algesia, effects that correlated with the relative densities of
CGRP immunoreactive c-fibers in dorsal horn lamina III.
Collectively, these results show that pain syndromes are not
a necessary consequence of astrocyte transplantation or of
the generation of astrocytes from transplanted precursor
cells at sites of spinal cord injury, but instead indicate that
the generation of specific subtypes of astrocyte, such as
GDAsCNTF, is responsible for this adverse effect.
D Di is sc cu us ss si io on n
This study provides several new discoveries related to the
treatment of traumatic spinal cord injury by cell trans-
plantation. We show for the first time that different types of
astrocytes derived from the same population of embryonic
glial precursor cells have markedly different effects on repair
and functional recovery when transplanted into the injured
adult spinal cord. Transplantation of GDAsBMP promoted
axon regeneration, neuroprotection and robust recovery of
function. In sharp contrast, transplantation of GDAsCNTF or of
undifferentiated GRPs did not provide any of these beneficial
effects (see Table 1). Moreover, transplantation of GDAsCNTF
or undifferentiated GRPs resulted in both mechanical
allodynia and thermal hyperalgesia, problems that were not
caused by transplantation of GDAsBMP. Our study provides
further evidence that astrocytes derived from BMP-treated
GRPs are a particularly promising population of cells for CNS
repair and provide the first identification of a specific glial cell
type - GDAsCNTF - that can induce pain-related syndromes
following transplantation into the injured spinal cord.
C Co on nt tr ro ol ll le ed d   d di if ff fe er re en nt ti ia at ti io on n   o of f   g gl li ia al l   p pr re ec cu ur rs so or rs s   a an nd d   s sp pi in na al l   c co or rd d
r re ep pa ai ir r
The remarkably consistent and robust support of endogenous
axon regeneration, neuroprotection and functional recovery
provided by transplantation of GDAsBMP in our previous [14]
and present studies and the equally consistent failure of GRP
transplantation to provide these benefits clearly show that
controlled differentiation of glial precursors prior to
transplantation to acute spinal cord injuries can result in
significantly better outcomes. This hypothesis is consistent
with previous studies showing failures of transplanted GRPs
to promote axon growth [31] or functional recovery after
spinal cord injury unless combined with additional
treatments. Genetic manipulation of GRP cells to express the
multifunctional-neurotrophin D15A before transplantation
[32], or their transplantation in combination with neuron-
restricted precursors (NRPs) [33], resulted in some locomotor
recovery, with both studies showing improvements of
approximately 2.5 points on the Basso, Beattie, and
Bresnahan (BBB) open-field locomotor test. However, even
the NRP/GRP-treated rats that had shown improved BBB
scores failed to show a statistically significant improvement
after grid-walk analysis [33]. As the NRP/GRP transplants
were carried out in animals with contusion spinal cord
injuries, the outcomes cannot be directly compared with our
current studies, but do indicate the importance of conducting
future experiments to compare the effects of NRP/GRP versus
GDABMP transplantation in promoting recovery from both
transection and contusion spinal cord injuries.
A striking and somewhat unexpected result of our study is that
the two populations of astrocytes derived by pre-
differentiation of embryonic spinal cord GRPs by two classical
astrogenesis signaling pathways had completely opposite
effects on axon regeneration, neuroprotection, functional
recovery and neuropathic pain after transplantation, clearly
demonstrating that not all astrocytes that can be derived from
glial precursors are beneficial for CNS repair. Previous studies
have shown functional differences in astrocytes from different
regions of the CNS in respect of promotion of neurogenesis,
neurite outgrowth, or promotion of axonal versus dendritic
specialization [34-37]. Our current study, however, is the first
to demonstrate that astrocytes generated by exposing the same
precursor cell to different signaling agents have markedly
different effects when transplanted into acute spinal cord
injuries.
F Fa ac ct to or rs s   r re eg gu ul la at ti in ng g   G GR RP P   d di if ff fe er re en nt ti ia at ti io on n   i in nt to o   b be en ne ef fi ic ci ia al l   a as st tr ro oc cy yt te es s
In the light of our new findings, the question arises as to
whether any astrocyte generated by exposure of precursor
cells to BMP would be suitable for use in repair of spinal
cord injuries. This may not be the case, however, as exposure
of O-2A progenitors cells (a type of glial progenitor that
arises later in development than GRP cells) to BMP generate
astrocytes with a phenotype that appears to be like that of
GDAsCNTF [38], and BMP treatment of acute spinal cord
injuries can promote scar formation [39]. These findings
suggest that glial precursors isolated from later stages of
neural development may not be able to generate beneficial
GDABMP-like astrocytes in response to BMP.
E En nd do og ge en no ou us s   G GD DA AC CN NT TF F- -l li ik ke e   a as st tr ro oc cy yt te es s   i in n   t th he e   i in nj ju ur re ed d   C CN NS S
It will be of great interest to determine whether the
Olig2+/GFAP+ cells generated in spinal cord injuries
(Figure 3c), cerebral cortex stab injuries [21] and in rodent
models of experimental autoimmune encephalomyelitis [20]
are astrocytes generated from endogenous O-2A progenitor
cells, and thus represent the long-sought in vivo counterpart of
the type-2 astrocytes generated from these progenitor cells in
vitro  [40]. Our findings that GDAsCNTF can become Olig2-
negative after transplantation shows that the phenotype of
such cells can be labile in vivo, as has also been seen in studies
of Olig2+ astrocytes during CNS development [41]. This raises
the possibility that the search for endogenous GDACNTF-like
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multiple time points after injury. Nonetheless, the fact that
astrocytes within adult CNS scar tissue share many
characteristics with GDAsCNTF, such as poor support of axon
growth and expression of Olig2 and inhibitory CSPGs,
supports the hypothesis that they are functionally similar.
G GD DA As s   a an nd d   s su up pp pr re es ss si io on n   o of f   a ax xo on n- -g gr ro ow wt th h- -i in nh hi ib bi it to or ry y   s sc ca ar r
f fo or rm ma at ti io on n
Our study sheds new light on the role of GDA-mediated
suppression of glial scar formation in supporting axon
regeneration across acute spinal cord injuries. Logic dictates
that improved alignment of host tissue can increase the
efficiency of axon growth into and out of a site of injury by
creating a shorter, less tortuous path for axons to follow.
Neurocan and NG2 are axon-growth-inhibitory CSPGs
[42,43] that are upregulated at sites of spinal cord injury
[18,44,45] and whose suppression has been shown to
correlate with the ability of adult sensory axons to cross
acute spinal cord injuries [46]. In light of our previous
finding that transplantation of GDAsBMP to acute dorsal
column transection injuries resulted in a remarkable align-
ment of host astrocytes within injury margins and a
transient suppression of neurocan and NG2 [14], we
proposed that these effects played significant roles in
promoting axon growth across GDABMP-bridged spinal cord
injuries.
Our current study shows that transplanted GDAsCNTF and
GRP cells promote the suppression of neurocan and NG2 in
host tissues to an extent comparable to that previously
observed for GDAsBMP at 4 days post-transplantation [14];
nevertheless, they completely fail to align host astrocytes or
support the regeneration of ascending dorsal column axons
across sites of injury. A suppression of CSPG expression
combined with a failure of axon regeneration has also
previously been shown after GRP transplantation into acute
spinal cord injuries [31]. Although these results do not rule
out the possibility that suppression of CSPGs in host tissues
may play an important role in the ability of GDAsBMP to
promote axon growth across sites of injury, they do show
that such suppression is not by itself sufficient to promote
axon growth. It may be that despite being able to suppress
expression of axon-growth-inhibitory CSPGs, GDAsCNTF and
GRPs transplanted in acute spinal cord injuries fail to
actively support axon growth and/or express molecules
themselves that actively inhibit it. These concepts are
supported by the expression of neurocan and NG2 by
transplanted GDAsCNTF and GRPs, a result that was not
observed for transplanted GDAsBMP  [14]. The low-level
expression of axon-growth-inhibitory CSPGs by GDAsBMP
compared with GDAsCNTF, both in vitro and within spinal
cord injuries, is one potential mechanism that might
account for the clear difference in the ability of these
astrocytes to support axon growth.
P Pr re ec cu ur rs so or r- -d de er ri iv ve ed d   a as st tr ro oc cy yt te es s, ,   s sp pi in na al l   c co or rd d   i in nj ju ur ry y   a an nd d   n ne eu ur ro op pa at th hi ic c
p pa ai in n
Some of the most important results of our experiments
concern the ability of both GDAsCNTF and GRP transplants to
cause mechanical allodynia and thermal hyperalgesia. Two
studies of NSC transplantation to acute traumatic spinal cord
injury sites in adult rats showed similar degrees of both
mechanical and thermal forelimb allodynia [15,16]. That
suppressing the differentiation of the transplanted NSCs to
astrocytes prevented the onset of allodynia [15] could be
interpreted to mean that all astrocytes generated from
precursor cells have the capacity to promote allodynia. It was
therefore crucial to determine whether the onset of allodynia
after spinal cord injury is a problem that applies generally to
the transplantation of astrocytes and astrocyte precursors. Our
finding that mechanical allodynia and thermal hyperalgesia
are caused by transplantation of GRPs and GDAsCNTF - but not
of GDAsBMP - shows that only specific types of astrocytes or
glial precursors cause these adverse outcomes.
Aberrant sprouting of CGRP-positive c-fibers has been shown
to correlate with the onset of neuropathic pain after spinal
cord injury [30]. We found a doubling of the density of
CGRP-positive c-fibers within lamina III of the dorsal horns
of injured spinal cords receiving GDACNTF or GRP transplants,
an effect that was also correlated with neuropathic pain after
transplantation of neural precursor cells into acute spinal
cord injuries [15,16]. Interestingly, a reduction in allodynia
and sprouting of CGRP+ c-fibers has been observed after
transplantation of mixed NRP/GRP populations to spinal
cord injuries [33]; however, the effects of GRP transplantation
alone on allodynia were not tested in that study. Whether this
benefit of combined NRP/GRP transplantation reflects
suppression of the generation of GDACNTF-like astrocytes at
the site of injury is an interesting question for the future.
It has long been a concern that therapies designed to promote
axon growth after spinal cord injury would result in sprouting
of CGRP+ c-fibers and the induction of neuropathic pain. Our
results show, however, that GDAsBMP have the remarkable
ability to promote functional recovery without inducing pain,
and promote axon regeneration without promoting aberrant
sprouting of CGRP+ c-fibers. These results also show for the
first time that two different types of precursor-derived
astrocytes can have markedly different effects on the growth
of different types of sensory axons.
G Gl li ia al l   a ac ct ti iv va at ti io on n   a an nd d   n ne eu ur ro op pa at th hi ic c   p pa ai in n   a af ft te er r   s sp pi in na al l   c co or rd d   i in nj ju ur ry y
Glial activation within the injured adult spinal cord is
thought to have an important role in the development and
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of glial cell function in neuropathic pain hypothesizes that
injury-activated microglia are critical for initiation of
enhanced pain perception via activation of astrocytes, and
that activated astrocytes and microglia are also involved in
the maintenance of neuropathic pain after traumatic spinal
cord injury [49]. It has been shown that increases in spinal
cord astrocytic GFAP expression following peripheral nerve
injury correlates with the development of neuropathic pain
[50] and that specific activation of microglia and astrocytes
in the adult rat spinal cord is sufficient to promote neuro-
pathic pain [51]. Whether transplanted GDAsBMP or
GDAsCNTF can alter the activation state of microglia,
whether these cells respond differently to the presence of
activated microglia in an acute spinal cord injury, or
whether transplantation of GDAsCNTF bypasses any require-
ment for activated microglia to initiate neuropathic pain,
are all presently unknown and will be the subject of future
investigations.
N Ne eu ur ro op pa at th hi ic c   p pa ai in n, ,   g gl li ia al l   s sc ca ar r   f fo or rm ma at ti io on n   a an nd d   g gp p1 13 30 0   r re ec ce ep pt to or r
a ac ct ti iv va at ti io on n
The results reported here may also prove relevant to a better
understanding of the role of gp130 agonists in promoting
glial scar formation and neuropathic pain syndromes. In
addition to its interactions with CNTF, the gp130 protein is
a shared receptor for several related cytokines, including
leukemia inhibitory factor (LIF) and interleukin-6 (IL-6,
which has tertiary structure homology with CNTF) [52]. In
some contexts, these agents may have beneficial effects on
the injured nervous system, such as promoting oligodendro-
cyte generation and survival as well as neuronal protection
[53-59]. Our results show, however, that exposure of glial
precursors to the gp130 agonist CNTF results in the
generation of astrocytes that are poorly supportive of axon
growth and promote pain when transplanted into spinal cord
injuries. CNTF, LIF and IL-6 are known to be upregulated at
sites of spinal cord injury [60-65] and it is possible that some
or all of these factors may also drive the differentiation of
local endogenous glial precursors to a GDACNTF-like
phenotype (Olig2+/GFAP+) that contributes to the formation
of axon-growth-inhibitory scar tissue. Our finding of
endogenous Olig2+/GFAP+ astrocytes within the margins of
control untreated spinal cord injuries lends at least
preliminary support to this hypothesis. Recent experiments
showing that blocking of the gp130 receptor suppressed scar
formation and improved functional recovery after spinal cord
injury [66], and that specific inhibition of CNTF induction of
astrocyte differentiation within transplanted fetal tissue
improved axon growth across acute spinal cord injuries [67],
also support this hypothesis. Future experiments will
determine whether blocking CNTF or gp130 receptor activity
in spinal injuries or after transplantation of undifferentiated
glial precursors will increase axon growth across the injury
and suppress the onset of neuropathic pain.
C Co on nc cl lu us si io on ns s
The results reported here lend significant new support to
our hypothesis that pre-differentiation of glial precursor
cells into a specific population of astrocytes such as
GDAsBMP before transplantation into spinal cord injuries
results in significantly better outcomes, and they also
provide further evidence that GDAsBMP are a particularly
promising cell type for promoting CNS repair. We have also
provided the first identification of a specific glial cell type -
GDAsCNTF - that is capable of inducing pain-related
syndromes following its transplantation into the injured
spinal cord. This clearly demonstrates that not all astrocytes
that can be derived from embryonic glial precursors have
beneficial effects in spinal injuries. As gp130 agonists are of
broad interest as inducers of astrocyte reactivity after injury
to the CNS, our present findings are of particular relevance
to the future study of gp130 agonists and glial precursors in
CNS scar formation and onset of allodynia. The generation
of a pain syndrome is one of the most adverse outcomes that
could result from cell transplantation therapy for spinal cord
injury [68-71], rivaled only by loss of remaining function or
increased mortality. Our findings demonstrate that a better
understanding of the origins and functional properties of
different subpopulations of astrocytes is required if we are to
safely utilize CNS stem or progenitor cell transplantation for
treating the injured or diseased adult CNS.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
I Is so ol la at ti io on n   o of f   G GR RP Ps s   a an nd d   g ge en ne er ra at ti io on n   o of f   G GD DA As s
A2B5+ GRPs were isolated by fluorescence activated cell
sorting (FACS) of dissociated cell suspensions from spinal
cords of embryonic day (E)13.5 transgenic Fischer 344 rat
embryos expressing the gene for human placental alkaline
phosphatase (hPAP) under the control of the ROSA26
promoter (TgN(R26ALPP)14EPS) [72]. GRPs were
maintained on a fibronectin/laminin substrate at 4 × 103 to 2
× 104 cells/cm2 in Dulbecco's modified eagle medium
(DMEM)/F12 Sato-medium supplemented with 10 ng/ml
basic fibroblast growth factor (bFGF). Passage number, days in
vitro, cell density and media conditions were tightly controlled
for experimental replicates. To differentiate GRPs before trans-
plantation, 10 ng/ml of human recombinant BMP-4 (R&D
Systems) or 10 ng/ml human recombinant CNTF (Peprotech)
were added to the culture media for 7 days to differentiate
them into astrocytes - GDAsBMP (A2B5-/GFAP+) and GDAsCNTF
(A2B5+/GFAP+), respectively. For in vitro induction
experiments, GRPs were seeded at 5,000 cells/cm2 on a
fibronectin/laminin substrate in DMEM/F12 Sato-medium
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switched as indicated and cells were allowed to differentiate
into astrocytes for up to 7 days. Medium was changed every
2 days. Parallel cultures were used for Western blot and
immunofluorescent analysis.
I In n   v vi it tr ro o i im mm mu un no of fl lu uo or re es sc ce en nc ce e
Cells grown on fibronectin/laminin-coated glass coverslips
were fixed for 5 minutes in 2% formaldehyde, rinsed and
blocked using 5% normal goat serum in Hanks balanced salt
solution (HBSS) with Hepes pH 6.8. For Olig2 and GFAP
labeling, cells were permeabilized using 0.1% Triton-X100 in
phosphate buffered saline (PBS) for 15 minutes. Anti-Olig2
(1:4000, Chemicon) and anti-GFAP (1:400, Cell Signaling)
were incubated at 4°C for 18 h. Anti-NG2 (Chemicon,
1:2000) staining was performed on live cells in growth
medium for 30 minutes prior to fixation with formaldehyde.
Fluorescently labeled, secondary anti-Ig antibodies (Alexa
488 and 568 conjugates, Invitrogen) were used at a 1:2000
dilution for 1 h at room temperature. Coverslips were
mounted on glass slides with ProLong Gold and viewed using
a Nikon 80i microscope equipped with a Spot RT camera.
Monochrome images of parallel samples were captured using
identical exposure times and gain settings, and merged as
pseudo-colored images. Both BMP- and CNTF-induced GDAs
were uniformly immunoreactive for human alkaline
phosphatase in vitro.
W We es st te er rn n   b bl lo ot t   a an na al ly ys si is s
After treatment of cultures for 5 days with conditions as
indicated, PBS-washed cells were harvested in XDP buffer (1%
Triton X100, 0.5% sodium deoxycholate in PBS pH 7.2)
supplemented with Complete Mini Protease Inhibitor
Cocktail (Roche). The protein concentration of cleared lysates
was determined using the Biorad DC protein assay. Samples
(25 µg of protein per sample) were fractionated using NuPage
4-12% gradient gels (Invitrogen) and then transferred to
polyvinylidene difluoride (PVDF) membranes (Perkin Elmer).
Membranes were blocked in 5% non-fat dry milk in Tris-
buffered saline containing 0.1% Tween-20 (Sigma) and then
incubated with primary antibodies at 4°C for 18 h. Antibodies
and dilutions used: NG2 (Chemicon, 1:1000), anti-
phosphacan (Developmental Studies Hybridoma Bank,
1:1000),  β-tubulin (Santa Cruz Biotechnology, 1:1000).
Horseradish-peroxidase-conjugated anti-mouse (PerkinElmer)
or anti-rabbit (Invitrogen) antibodies were applied to washed
blots and visualized using Luminol reagent (Santa Cruz
Biotechnology) and Kodak X-OMAT LS X-ray film. Film was
developed using a Kodak X-OMAT 3000RA processor.
Densitometric analysis of scanned film images was performed
using NIH Image-J software. Expression levels of phosphacan
(320-340 kDa band) and NG2 (270-300 kDa band),
respectively, were normalized for each sample to β-tubulin
(52 kDa) expression. All Western blot experiments were
conducted in triplicate and results were compared using the
Student’s t-test, p < 0.05.
H Ho om mo og ge en ne ei it ty y   o of f   c ce el ll l   p po op pu ul la at ti io on ns s   f fo or r   t tr ra an ns sp pl la an nt ta at ti io on n
To confirm cell phenotype and homogeneity before trans-
plantation, small volumes of cell suspensions were plated
onto glass coverslips and labeled with A2B5 and anti-GFAP
antibodies. GRP cell suspensions occasionally contained a
small number (average of 2.1%) of A2B5+/GFAP+ cells, and
GDACNTF cell suspensions included a small number (average
1.3%) of A2B5+/GFAP- cells. To ensure that GDABMP suspen-
sions for transplantation did not contain undifferentiated
GRPs or cells with the phenotype of CNTF-induced astrocytes
(A2B5+/GFAP+), potential contaminating cell types were
removed from the suspension by immuno-panning with the
A2B5 antibody. For transplantation, GRPs or GDAs were
suspended in HBSS at a density of 30,000 cells/µl.
S Sp pi in na al l   c co or rd d   i in nj ju ur ry y   m mo od de el ls s   a an nd d   c ce el ll l   t tr ra an ns sp pl la an nt ta at ti io on n
Adult female Sprague Dawley rats (3 months old, Harlan)
were used in all in vivo spinal cord injury experiments (see
Table 2 for numbers of rats used per experiment) and were
http://jbiol.com/content/7/7/24 Journal of Biology 2008, Volume 7, Article 24 Davies et al. 24.15
Journal of Biology 2008, 7 7: :24
T Ta ab bl le e   2 2
N Nu um mb be er rs s   o of f   a an ni im ma al ls s   p pe er r   e ex xp pe er ri im me en nt ta al l   g gr ro ou up p   i in n   v vi iv vo o
Time Control 
Spinal cord injury model Details points injury +GDABMP +GDACNTF +GRP
Dorsal column injury Analysis of scar formation and transplanted  4 days 4 4 4 4
cell phenotype 8 days 4 4 4 4
Dorsal column injury Analysis of endogenous axon growth 8 days - 5 5 5
Dorsal column injury Analysis of axon growth from transplanted  8 days 4 - 4 -
GFP+ sensory neurons
Dorsolateral funiculus injury Analysis of locomotor recovery, allodynia  5 weeks 9 9 9 9
and neuroprotectionanesthetized by injection of a cocktail containing ketamine
(42.8 mg/ml), xylazine (8.2 mg/ml), and acepromazine
(0.7 mg/ml). For dorsal column injuries (Figure 1a-c), the
right-side dorsal column was unilaterally transected between
cervical vertebrae 1 and 2 using a 30-gauge needle as a blade
(see also [18,25,46]). Injuries extended to a depth of 1 mm
and extended laterally 1 mm from the midline. For rubro-
spinal tract injuries, unilateral transections of the right-side
dorso-lateral funiculus including the rubrospinal pathway
were conducted at the C3/C4 spinal cord level with Fine
Science Tools micro-scissors. Injuries extended to a depth of
1 mm and extended medially 1 mm from the lateral pial
surface of the spinal cord (Figure 1d). Transection spinal cord
injuries were used instead of contusion injuries in order to
minimize axon sparing and permit more accurate
quantification of axon growth across injury sites bridged with
GDACNTF, GDABMP or GRPs. The use of an intervertebral
surgery approach in combination with discrete transection
injuries of the dorsolateral funiculus also results in highly
consistent deficits in grid-walk locomotor performance and
atrophy of red nucleus neurons [14].
A total of 6 µl of GDACNTF, GDABMP or GRP suspensions
(30,000 cells/µl; 180,000 cells total) per animal were acutely
transplanted into six different sites in dorsal column injuries;
that is, two injections each into medial and lateral regions of
the rostral and caudal injury margins, and two injections into
medial and lateral regions of the injury center (Figure 1b). All
dorsal column injury experiments were conducted in the
absence of immunosuppressants. Transplants of either
GDAsBMP, GDAsCNTF or undifferentiated GRPs were injected in
an identical pattern into injuries of the dorsolateral funiculus
and a total of 6 µl of GDA or GRP cell suspension (30,000
cells/µl; 180,000 cells) injected per injury site. Control injured
rats were injected with 6 µl HBSS. All control or cell
transplanted rats in the dorsolateral funiculus injury groups
were given daily injections of cyclosporine (1 mg/100 g body
weight) beginning the day before injury/transplantation
through to experimental endpoints.
A Ad du ul lt t   D DR RG G   n ne eu ur ro on n   t tr ra an ns sp pl la an nt ta at ti io on n
Single-cell suspensions of adult mouse sensory neurons were
prepared from 10-12-week-old transgenic mice expressing the
gene for EGFP [73] as previously described [25,46,74]. No
growth factors were added to the neuron suspension. Five
hundred nanoliters of the neuron suspension (approximately
1,500 neurons/µl) were acutely microtransplanted into dorsal
column white matter approximately 500 µm caudal to the
injury site (Figure 1c).
H Hi is st to ol lo og gy y
At 4 days, 8 days and 5 weeks post-surgery animals were
deeply anesthetized and transcardially perfused with 0.1 M
PBS followed by 4% paraformaldehyde in 0.1 M PBS.
Dissected spinal cords were cryoprotected in a 30% sucrose/
PBS solution at 4°C overnight. Tissue was embedded in
optimal cutting temperature (OCT) medium (Sakura
Finetek) and quickly frozen. Serial 25-µm-thick frozen
sections were cut in the sagittal plane and air dried onto
gelatin-coated glass slides. All tissue sections were washed in
PBS, blocked with 4% normal goat serum in solution with
0.1% Triton/PBS for 30 minutes, then incubated with
appropriate primary antibodies in the blocking solution
overnight at 4°C. Secondary antibody incubations were for
45 minutes at room temperature.
The following primary antibodies were used: monoclonal
anti-GFAP (Sigma) and polyclonal anti-GFAP (Sigma); poly-
clonal anti-NG2 (Chemicon); monoclonal anti-neurocan
(clone 1F6, Developmental Studies Hybridoma Bank);
polyclonal anti-GFP (Molecular Probes); monoclonal anti-
hPAP (Sigma); polyclonal anti-hPAP (Fitzgerald); polyclonal
anti-Olig2 (Chemicon); polyclonal anti-CGRP (Chemicon).
Cy5, Cy2 (Jackson), Alexa-488 and Alexa-594 (Molecular
Probes) conjugated secondary antibodies were used to
visualize primary antibody binding. All secondary antibodies
were pre-absorbed against rat serum. To control for
nonspecific secondary antibody binding, adjacent sections
were also processed as described above without primary
antibodies. Some sections were counterstained with DAPI to
show nuclei. Labeled sections were examined and imaged
using a Zeiss Observer Z1 fluorescence light microscope or a
Zeiss 510 Meta confocal microscope. Antigen co-localization
and cellular associations were determined with Zeiss Confocal
image analysis software. Spinal cord white matter rostral to the
injury site is shown to the left in all figures with images of
sections cut in the sagittal plane.
T Tr ra ac ci in ng g   a an nd d   q qu ua an nt ti if fi ic ca at ti io on n   o of f   e en nd do og ge en no ou us s   a as sc ce en nd di in ng g   d do or rs sa al l
c co ol lu um mn n   a ax xo on ns s
In the dorsal column injury model, ascending endogenous
axons were traced by injection of 10% biotinylated dextran
amine in sterile PBS (BDA, Molecular Probes) at 8 days prior
to an experimental endpoint. BDA tracer was injected to a
depth of 0.5 mm into the right-side, cuneate and gracile white
matter at the C4/C5 spinal level (Figure 1c). For histological
analysis of BDA-labeled axons, 25-µm serial sagittal sections
were collected and processed for immunohistochemistry as
described above. BDA was visualized by incubating tissue
sections with the Vectastain ABC solution (Vector Labs), and
further intensified with the Tyramide-Alexa 488 reagent
(Molecular Probes).
For quantification of axon regeneration, the number of
BDA-labeled axons was counted in every third tissue section
spanning the medial-lateral extent of dorsal column injury
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directly at the injury center; 0.5 mm, 1.5 mm and 5 mm
rostral to the injury site; and within the dorsal column
nuclei. To control for differences in axon tracing/labeling
efficiency between animals, the numbers of BDA-labeled
axons counted within the injury center and at all rostral
sites were normalized to the number of BDA-labeled axons
detected 0.5 mm caudal to the injury site for each tissue
section examined. The normalized values from each tissue
section for each separate animal (control, GRP-, GDABMP-
and GDACNTF-transplanted rats) were averaged to generate
values for each animal. The values for each animal (n =5
per group) were then averaged and displayed graphically.
ANOVA or t-tests were performed as appropriate, p < 0.01.
Q Qu ua an nt ti if fi ic ca at ti io on n   o of f   C CG GR RP P   c c- -f fi ib be er r   s sp pr ro ou ut ti in ng g
For quantifying changes in the density of CGRP immuno-
reactivity in rats that had received right-side dorso-lateral
funiculus transection injuries, 20-µm-thick serial cross-
sections were labeled with anti-CGRP antibody. Images
were captured of the right-side dorsal horn (ipsilateral to
the injury/transplantation site) from five randomly chosen
sections at the C6 spinal level from five animals in each
experimental group. Analysis was conducted at the C6
spinal level because this is the level that maps to the
dermatome as tested for forepaw mechanical sensitivity in
rats [75]. All images were captured at the same magnifi-
cation, resolution and exposure time. Using ImagePro
image analysis software, lamina III of the dorsal horn was
selected as the region of interest and the number of pixels
within lamina III that were CGRP-positive was recorded.
The total number of pixels within each region of interest
was also recorded and used to normalize CGRP pixel counts
between sections and thus permit comparison of the density
of CGRP immunoreactivity between experimental groups.
Data are presented as the average percentage of CGRP-
positive pixels per area sampled (number of CGRP-positive
pixels divided by the total number of pixels per region of
interest) and analyzed by ANOVA followed by Tukey’s post
test. An ANOVA analysis was also carried out to ensure that
the total area sampled between groups was not significantly
different (p > 0.05).
G Gr ri id d- -w wa al lk k   b be eh ha av vi io or ra al l   a an na al ly ys si is s
Two weeks before surgery, rats were trained to walk across a
horizontal ladder (Foot Misplacement Apparatus, Columbus
Instruments) and only rats that consistently crossed without
stopping were selected for experiments. The grid-walk test is
a sensitive measure of the ability of rats to step rhythmically
and coordinate accurate placement of both fore and hind
limbs [27]. For analysis of recovery of locomotor function
in GDABMP- and GDACNTF-transplanted versus untreated
injured controls, trained rats were randomly assigned to one
of three groups: RST injury + GDABMP + cyclosporine
(n = 9); RST injury + GDACNTF + cyclosporine (n = 9); RST
injury + suspension media + cyclosporine (n = 9). One day
before surgery (baseline) and at 3, 7, 10, 14, 17, 21, 24 and
28 days post-surgery, each rat was tested three times and the
number of mis-steps from each trial was averaged to
generate a daily score for each animal. Two-way repeated
measures ANOVA and Tukey post test (p < 0.05) were
applied to analyze the data.
S Se en ns so or ry y   t te es st ti in ng g
Mechanical and thermal sensitivity were measured the day
before injury/transplantation (baseline) and then at 2, 3, 4
and 5 weeks post-injury. To test for changes in mechanical
sensitivity, graded Von Frey filaments (Stoelting) were
applied in ascending order to the plantar surface of the right
forepaw. The lowest force that caused paw withdrawal
accompanied by licking, paw-guarding behavior or vocaliza-
tion at least three times per five trials was determined to be
the mechanical threshold. Thermal sensitivity was tested
with the hot-plate analgesia instrument (Stoelting). The
temperature of the plate was held constant at 55°C, rats
were placed on the plate, and the latency (in seconds) to
licking of paws or vocalization was recorded. ANOVA
followed by Tukey’s post test analysis was applied to
determine statistical significance of any change from
baseline behavior (p < 0.05). Analysis was conducted on the
same GDABMP-treated, GDACNTF-treated, and medium-
injected control rats with spinal cord injury that were used
for grid-walk analysis. An additional group of GRP-trans-
planted rats with dorsolateral funiculus injuries (n = 9) was
also similarly tested for mechanical allodynia and thermal
hyperalgesia at times ranging from 2 to 5 weeks after injury/
transplantation.
Q Qu ua an nt ti if fi ic ca at ti io on n   o of f   r re ed d   n nu uc cl le eu us s   n ne eu ur ro on ns s
At 5 weeks after injury/transplantation, animals were eutha-
nized and 25-µm serial frozen sections were cut in the
coronal plane from the brains of rats that had undergone
behavioral analysis. Every third section through the rostro-
caudal extent of the red nucleus was stained with 0.2%
cresyl violet. Standard, design-based stereology methods
(CAST software, Olympus) were used to quantify numbers
of neurons in both red nuclei in six out of nine RST-injured
rats per group that had received GDACNTF, GDABMP, or GRP
transplants or control injections of culture medium. An
optical fractionator was applied to left and right side red
nuclei from every sixth section. Cell bodies greater than
20 µm in diameter and with characteristic neuronal mor-
phology were counted. The numbers of neurons counted in
the left-side (injured) red nucleus were normalized to
counts obtained for the uninjured right-side nucleus for
each animal. The values for each animal within a group
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performed to determine the statistical significance of the
difference between the groups (p < 0.01).
All procedures were performed under guidelines of the
National Institutes of Health and approved by the
Institutional Animal Care and Utilization Committee
(IACUC) of Baylor College of Medicine, Houston, TX or the
IACUC of University of Colorado Health Sciences Center,
Denver, CO, or the IACUC of University of Rochester
Medical Center, Rochester, NY.
A Ad dd di it ti io on na al l   d da at ta a   f fi il le es s
Additional data file 1 is a figure showing that transplanted
GRP cells express neurocan and NG2, but suppress host
expression of these molecules at 4 days post transplantation
to dorsal column injuries. Additional data file 2 is a figure
showing failure of axons to regenerate across GDACNTF-
transplanted injuries. Additional data file 3 is a figure
showing neuroprotection of injured red nucleus neurons.
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